<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical manifestations, diagnosis, and treatment of Alport syndrome (hereditary nephritis)</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical manifestations, diagnosis, and treatment of Alport syndrome (hereditary nephritis)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical manifestations, diagnosis, and treatment of Alport syndrome (hereditary nephritis)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Clifford E Kashtan, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tej K Mattoo, MD, DCH, FRCP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard J Glassock, MD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Alport syndrome (also referred to as hereditary nephritis) is an inherited progressive form of glomerular disease that is often associated with sensorineural hearing loss and ocular abnormalities [<a href="#rid1">1</a>]. Alport syndrome is a primary basement membrane disorder arising from pathogenic variants in genes encoding several members of the collagen IV protein family.</p><p>The clinical manifestations, diagnosis, and treatment of Alport syndrome will be reviewed here. The pathogenesis, genetics, and pathology of Alport syndrome are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6086.html" rel="external">"Genetics, pathogenesis, and pathology of Alport syndrome (hereditary nephritis)"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">GENETICS</span><span class="headingEndMark"> — </span>Alport syndrome is a genetically heterogeneous disease that results from disease-causing variants in genes encoding the alpha-3, alpha-4, and alpha-5 chains of collagen IV [<a href="#rid1">1</a>]. These collagen IV alpha chains are normally located in various basement membranes of the kidney, cochlea, and eye. Abnormalities in these chains result in defective basement membranes at these sites, leading to the clinical features of this disorder (ie, progressive glomerular disease, sensorineural hearing loss, and ocular abnormalities). (See  <a class="medical medical_review" href="/z/d/html/6086.html" rel="external">"Genetics, pathogenesis, and pathology of Alport syndrome (hereditary nephritis)", section on 'Genetics'</a> and <a class="local">'Clinical manifestations and course'</a> below.)</p><p>Transmission of Alport syndrome can be X-linked, autosomal recessive, autosomal dominant, or, in rare cases, digenic. (See  <a class="medical medical_review" href="/z/d/html/6086.html" rel="external">"Genetics, pathogenesis, and pathology of Alport syndrome (hereditary nephritis)", section on 'Genetics'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>X-linked transmission accounts for the majority of affected patients who exhibit progressive kidney disease and hearing loss and arises from variants in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F303630&amp;token=tEpDslnpc0F0kICl%2Fz7sFfZgq3tROP1vh4DhckKBw6GuDNPxjxwS5lxr5ffuoR0b&amp;TOPIC_ID=6093" target="_blank"><i>COL4A5</i></a> gene on the X chromosome.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Autosomal recessive disease accounts for 10 to 15 percent of patients and arises from genetic defects in either the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F120070&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1RjfaNRysdmhVCcBiOUYk1V&amp;TOPIC_ID=6093" target="_blank"><i>COL4A3</i></a> or <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F120131&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1TpD72nzlbuUDIfJV2QRuro&amp;TOPIC_ID=6093" target="_blank"><i>COL4A4</i></a> genes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Autosomal dominant disease appears to account for 20 to 30 percent of patients with progressive kidney disease and arises from heterozygous variants in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F120070&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1RjfaNRysdmhVCcBiOUYk1V&amp;TOPIC_ID=6093" target="_blank"><i>COL4A3</i></a> or <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F120131&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1TpD72nzlbuUDIfJV2QRuro&amp;TOPIC_ID=6093" target="_blank"><i>COL4A4</i></a> genes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some families exhibit digenic inheritance due to transmission of variants in two of the three genes (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F120070&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1RjfaNRysdmhVCcBiOUYk1V&amp;TOPIC_ID=6093" target="_blank"><i>COL4A3</i></a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F120131&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1TpD72nzlbuUDIfJV2QRuro&amp;TOPIC_ID=6093" target="_blank"><i>COL4A4</i></a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F303630&amp;token=tEpDslnpc0F0kICl%2Fz7sFfZgq3tROP1vh4DhckKBw6GuDNPxjxwS5lxr5ffuoR0b&amp;TOPIC_ID=6093" target="_blank"><i>COL4A5</i></a>).</p><p></p><p class="headingAnchor" id="H198375925"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Alport syndrome has been reported in hundreds of unrelated kindreds that represent all geographic and ethnic groups. Although the overall incidence in the general population is unknown, data from the United States demonstrates Alport syndrome accounts for 3 percent of children with kidney failure (previously referred to as end-stage kidney disease) and 0.2 percent of adults with kidney failure [<a href="#rid2">2</a>].</p><p>Among children undergoing kidney biopsy, the incidence of Alport syndrome has varied from 1 to 12 percent depending on the indication for biopsy [<a href="#rid2">2-5</a>].</p><p>The gene frequency of Alport syndrome in the United States has been estimated at 1:5000 to 10,000, suggesting that there are approximately 30,000 to 60,000 affected individuals in the United States [<a href="#rid6">6</a>]. In Sweden, the risk of X-linked Alport syndrome was estimated to be 1 in every 17,000 live male births [<a href="#rid7">7</a>]. More recent studies have provided estimates of the prevalence of pathogenic variants in the three collagen type IV genes using sequencing databases: <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F303630&amp;token=tEpDslnpc0F0kICl%2Fz7sFfZgq3tROP1vh4DhckKBw6GuDNPxjxwS5lxr5ffuoR0b&amp;TOPIC_ID=6093" target="_blank"><i>COL4A5</i></a>, 1 in 2320 individuals; heterozygous <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F120070&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1RjfaNRysdmhVCcBiOUYk1V&amp;TOPIC_ID=6093" target="_blank"><i>COL4A3</i></a> and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F120131&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1TpD72nzlbuUDIfJV2QRuro&amp;TOPIC_ID=6093" target="_blank"><i>COL4A4</i></a> variants, 1 in 106 individuals; compound heterozygous variants in <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F120070&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1RjfaNRysdmhVCcBiOUYk1V&amp;TOPIC_ID=6093" target="_blank"><i>COL4A3</i></a> and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F120131&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1TpD72nzlbuUDIfJV2QRuro&amp;TOPIC_ID=6093" target="_blank"><i>COL4A4</i></a>, 1 in 88,866 individuals [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H3"><span class="h1">CLINICAL MANIFESTATIONS AND COURSE</span><span class="headingEndMark"> — </span>The classical presentation of Alport syndrome is based on clinical manifestations of affected males with X-linked disease. These features include glomerular disease that progresses to kidney failure, ocular abnormalities (eg, anterior lenticonus), sensorineural hearing loss, family history of male relatives with hematuria associated with kidney failure and deafness, and female relatives with hematuria.</p><p>Clinical presentation and course in patients with autosomal recessive disease are similar to those with X-linked disease. Patients with autosomal dominant disease generally exhibit more gradual loss of kidney function [<a href="#rid9">9,10</a>]. Sensorineural hearing loss and ocular anomalies are common in the X-linked and autosomal recessive forms of Alport syndrome but are unusual in patients with autosomal dominant disease. (See <a class="local">'Genetics'</a> above.)</p><p class="headingAnchor" id="H4"><span class="h2">Kidney manifestations</span><span class="headingEndMark"> — </span>The initial kidney manifestation of Alport syndrome is asymptomatic persistent microscopic hematuria, which is present in early childhood in affected patients. Since screening urinalysis is seldom performed in routine pediatric primary care, microscopic hematuria may not be detected unless the patient is screened because of an affected family member or found as an incidental finding for another issue (see  <a class="medical medical_review" href="/z/d/html/6089.html" rel="external">"Evaluation of microscopic hematuria in children", section on 'Asymptomatic isolated microscopic hematuria'</a>). Gross hematuria may be the initial presenting finding and often occurs after an upper respiratory infection [<a href="#rid11">11</a>]. However, recurrent episodes of gross hematuria are not uncommon, especially during childhood. Males without hematuria by the age of 10 years are unlikely to have Alport syndrome [<a href="#rid2">2</a>]. Patients with Alport syndrome have normal serum complement component 3 (C3) levels.</p><p>In early childhood, the serum creatinine and blood pressure are normal. Over time, proteinuria, hypertension, and progressive kidney insufficiency develop. Kidney failure usually occurs between the ages of 16 and 35 years in patients with X-linked or autosomal recessive disease. In some families, the course is more indolent with kidney failure being delayed until age 45 to 70, especially in those with autosomal dominant Alport syndrome.</p><p>In females with X-linked Alport syndrome, recurrent episodes of gross hematuria, proteinuria, hearing loss, and diffuse glomerular basement membrane (GBM) thickening and lamellation are associated with more severe kidney dysfunction and kidney failure at an earlier age [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Hearing loss</span><span class="headingEndMark"> — </span>Bilateral sensorineural hearing loss is common in patients with X-linked and autosomal recessive Alport syndrome [<a href="#rid13">13,14</a>]. Hearing loss typically begins in the high frequency range and progresses over time to frequencies in the range of conversational speech. One study of families with X-linked disease reported that audiologic testing detected hearing loss in 85 percent of affected males and 18 percent of female heterozygotes by 15 years of age [<a href="#rid11">11</a>]. In general, the rate of hearing loss is similar to the progression of kidney insufficiency, although complete hearing loss that is unresponsive to hearing aids is unusual.</p><p class="headingAnchor" id="H7"><span class="h2">Ocular manifestations</span><span class="headingEndMark"> — </span>Several ocular defects involving the lens, retina, and cornea have been reported in patients with Alport syndrome [<a href="#rid15">15,16</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Lens – Anterior lenticonus is a regular conical protrusion on the anterior aspect of the lens due to thinning of the lens capsule  (<a class="graphic graphic_figure graphicRef113728" href="/z/d/graphic/113728.html" rel="external">figure 1</a>). It occurs in 20 to 30 percent of males with X-linked Alport syndrome and is pathognomonic of the disease. Lenticonus can be complicated by the presence of subcapsular cataracts, which may lead to loss of visual acuity. (See  <a class="medical medical_review" href="/z/d/html/6270.html" rel="external">"Cataract in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Retina – Retinal changes are usually asymptomatic, and, when there is anterior lenticonus, they are always present [<a href="#rid17">17</a>]. The changes consist of bilateral white or yellow granulations that are superficially located in the retina surrounding the foveal area (also referred to as dot and fleck or fleck retinopathy) [<a href="#rid18">18</a>]. These findings are also specific for Alport syndrome. Some patients have developed macular holes with impaired vision [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cornea – Corneal changes in patients with Alport syndrome can include posterior polymorphous dystrophy and recurrent corneal erosion, which can cause severe ocular pain.</p><p></p><p class="headingAnchor" id="H9"><span class="h2">Leiomyomatosis</span><span class="headingEndMark"> — </span>Leiomyomas are benign tumors characterized by visceral smooth muscle overgrowth within the respiratory, gastrointestinal, and female reproductive tracts. They are found in 2 to 5 percent of patients with X-linked Alport syndrome who have chromosomal microdeletion at the 5' ends of <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F303630&amp;token=tEpDslnpc0F0kICl%2Fz7sFfZgq3tROP1vh4DhckKBw6GuDNPxjxwS5lxr5ffuoR0b&amp;TOPIC_ID=6093" target="_blank"><i>COL4A5</i></a>, which extend into the adjacent <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F303631&amp;token=tEpDslnpc0F0kICl%2Fz7sFfZgq3tROP1vh4DhckKBw6Gb%2Bjs8Vg3v5ghAGYrmyIpe&amp;TOPIC_ID=6093" target="_blank"><i>COL4A6</i></a> gene [<a href="#rid20">20,21</a>].</p><p class="headingAnchor" id="H23922451"><span class="h2">Arterial disease</span><span class="headingEndMark"> — </span>Aneurysms of the thoracic and abdominal aorta have been reported in relatively young male patients, as well as a single case of intracranial aneurysm [<a href="#rid22">22-24</a>].</p><p class="headingAnchor" id="H757559572"><span class="h1">PHENOTYPE-GENOTYPE CORRELATION</span><span class="headingEndMark"> — </span>The tempo of progressive kidney dysfunction depends, at least in part, on the underlying variant.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>X-linked Alport syndrome</strong> – For individuals with X-linked Alport syndrome, the presence of truncating variants (such as deletions and nonsense mutations) is associated with more rapidly progressive disease (both kidney and extrarenal) compared with missense mutations [<a href="#rid2">2,25-29</a>]. This was illustrated in the following reviews of families with X-linked Alport syndrome that demonstrated the correlation between kidney failure and types of variants in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F303630&amp;token=tEpDslnpc0F0kICl%2Fz7sFfZgq3tROP1vh4DhckKBw6GuDNPxjxwS5lxr5ffuoR0b&amp;TOPIC_ID=6093" target="_blank"><i>COL4A5</i></a> gene.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the first study of 195 European families, the risk of kidney failure by 30 years of age for male patients with missense variants; splice-site variants; and large deletion, nonsense, or frameshift variants was 50, 70, and 90 percent, respectively [<a href="#rid28">28</a>]. Large rearrangements of the <em>COL</em>4<em>A</em>5 gene or any variants that shift the reading frame of the gene were also associated with earlier onset of hearing loss and a higher incidence of anterior lenticonus [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the second study of 175 families from the United States, the average age of onset for kidney failure for male patients with missense, splice-site, and truncating variants was 37, 28, and 25 years of age, respectively [<a href="#rid29">29</a>]. Variants located closer to the 5' end of the gene were associated with an earlier onset of kidney failure and an increased risk of ocular changes and hearing loss than those located closer to the 3' end. Patients with splice-site or truncating variants were also more likely to have ocular abnormalities and hearing loss.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heterozygous females with X-linked disease</strong> – Females with X-linked Alport syndrome are heterozygous for variants in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F303630&amp;token=tEpDslnpc0F0kICl%2Fz7sFfZgq3tROP1vh4DhckKBw6GuDNPxjxwS5lxr5ffuoR0b&amp;TOPIC_ID=6093" target="_blank"><i>COL4A5</i></a> gene. They have a range of clinical findings due to lyonization, by which only one X chromosome is active per cell. As a result, approximately one-half of their cells will express the mutant <em>COL4A5</em> gene and the remaining cells will express the normal <em>COL4A5</em> gene, leading to a variable phenotype that is generally less severe than in affected males.</p><p></p><p class="bulletIndent1">This was shown in a study of the natural history of female heterozygotes with proven <em>COL4A5</em> mutations [<a href="#rid30">30</a>]. Among female heterozygotes followed in 195 affected families, the incidence of kidney failure before age 40 was 12 percent, compared with 90 percent in affected males [<a href="#rid28">28</a>]. With increasing age, there was an increased risk of progressive kidney disease, with a 30 percent probability of developing kidney failure by age 60 in these females. However, this may be an overestimate since approximately one-third of the females, most likely less severely affected, were lost to follow-up. There was variation in phenotypes among family members with the same genotype, most likely due to the variability of gene expression due to lyonization.</p><p></p><p class="bulletIndent1">Risk factors for chronic kidney disease in female heterozygotes include episodic gross hematuria in childhood, sensorineural deafness, proteinuria, and presence of the characteristic lamellation of the basement membrane (GBM) associated with Alport syndrome on kidney biopsy [<a href="#rid30">30-33</a>]. By comparison, female heterozygotes with only asymptomatic hematuria by the age of 30 to 40 years have a relatively small risk of developing kidney failure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autosomal recessive Alport syndrome</strong> – Individuals with autosomal recessive Alport syndrome due to biallelic pathogenic variants in <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F120070&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1RjfaNRysdmhVCcBiOUYk1V&amp;TOPIC_ID=6093" target="_blank"><i>COL4A3</i></a> and/or <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F120131&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1TpD72nzlbuUDIfJV2QRuro&amp;TOPIC_ID=6093" target="_blank"><i>COL4A4</i></a> have similar disease severity to males with X-linked disease. In a systematic review of a referral population, nearly all such individuals had hematuria and proteinuria and 60 percent had end-stage kidney disease [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autosomal dominant disease</strong> – Individuals with autosomal dominant Alport syndrome due to a heterozygous <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F120070&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1RjfaNRysdmhVCcBiOUYk1V&amp;TOPIC_ID=6093" target="_blank"><i>COL4A3</i></a> or <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F120131&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1TpD72nzlbuUDIfJV2QRuro&amp;TOPIC_ID=6093" target="_blank"><i>COL4A4</i></a> variant have a highly variable phenotype. In a referral population, clinical manifestations included hematuria (95 percent), proteinuria (46 percent), chronic kidney disease (29 percent), end-stage kidney disease (15 percent), hearing loss (16 percent), and ocular manifestations (3 percent) [<a href="#rid34">34</a>]. However, a population-based study reported a much higher proportion of individuals with asymptomatic or minimally symptomatic disease [<a href="#rid35">35</a>]. Most participants had not been diagnosed with Alport syndrome, and only 6 percent had end-stage kidney disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> – A contiguous gene syndrome consisting of X-linked Alport syndrome, midface hypoplasia, and intellectual disability resulting from chromosomal microdeletion involving the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F303630&amp;token=tEpDslnpc0F0kICl%2Fz7sFfZgq3tROP1vh4DhckKBw6GuDNPxjxwS5lxr5ffuoR0b&amp;TOPIC_ID=6093" target="_blank"><i>COL4A5</i></a> gene and adjacent genes has been described [<a href="#rid36">36</a>].</p><p></p><p class="headingAnchor" id="H10"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of Alport syndrome is made by molecular genetic testing or skin or kidney biopsy  (<a class="graphic graphic_algorithm graphicRef115552" href="/z/d/graphic/115552.html" rel="external">algorithm 1</a>) [<a href="#rid37">37</a>].</p><p>If cost or accessibility is not an issue, we prefer using molecular genetic next-generation sequencing analysis to confirm the diagnosis of Alport syndrome  (<a class="graphic graphic_algorithm graphicRef115552" href="/z/d/graphic/115552.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Individuals, especially male patients, with a positive family history for persistent hematuria and/or kidney failure</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with chronic kidney disease and sensorineural deafness and/or characteristic ocular findings regardless of family history</p><p></p><p class="headingAnchor" id="H12"><span class="h2">Molecular genetic testing</span><span class="headingEndMark"> — </span>Molecular genetic testing is the diagnostic procedure of choice because it is noninvasive and has a high degree of sensitivity and specificity [<a href="#rid38">38,39</a>]. Since the rate of progression of kidney disease may be dependent on the underlying specific variant, molecular analysis may provide more reliable prognostic information than either kidney or skin biopsy.</p><p>The choice of molecular testing is based on whether there is a family history of Alport syndrome  (<a class="graphic graphic_algorithm graphicRef115552" href="/z/d/graphic/115552.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Family history of Alport syndrome</strong> – For patients with a family history of Alport syndrome with an identified pathogenic variant, targeted testing for the presumed gene variant is preferred. If targeted mutational analysis reveals that the patient has the same genetic variant as that identified in the patient's family member(s) with Alport syndrome, a diagnosis of Alport syndrome is confirmed. For patients in whom the targeted mutational analysis does <strong>not</strong> detect the same genetic mutation as that identified in the patient's family member(s) with Alport syndrome, a kidney biopsy is performed for diagnosis.</p><p></p><p class="bulletIndent1">Direct mutational (targeted) analysis of coding sequence (ie, messenger ribonucleic acid [mRNA]), rather than genomic deoxyribonucleic acid (DNA), may provide a less laborious and more sensitive method for the detection of splice-site variants [<a href="#rid40">40-43</a>]. Since <em>COL4A5</em> mRNA is expressed in the skin and hair roots, analysis of cells from these sites may allow a relatively noninvasive diagnostic test but may not be commercially available [<a href="#rid40">40,44,45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features or nonspecific family history</strong> – For patients without a known family history of Alport syndrome but with clinical features suggesting this disorder (ie, kidney manifestations and either nonrenal findings [ocular and sensorineural deafness] or a family history of hematuria or kidney failure), next-generation DNA sequencing is performed. For patients in whom no pathogenic variant is detected, a kidney biopsy is performed for diagnosis.</p><p></p><p class="bulletIndent1">Next-generation sequencing allows simultaneous analysis of the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F120070&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1RjfaNRysdmhVCcBiOUYk1V&amp;TOPIC_ID=6093" target="_blank"><i>COL4A3</i></a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F120131&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1TpD72nzlbuUDIfJV2QRuro&amp;TOPIC_ID=6093" target="_blank"><i>COL4A4</i></a>, and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F303630&amp;token=tEpDslnpc0F0kICl%2Fz7sFfZgq3tROP1vh4DhckKBw6GuDNPxjxwS5lxr5ffuoR0b&amp;TOPIC_ID=6093" target="_blank"><i>COL4A5</i></a> genes and offers advantages in screening time and cost [<a href="#rid46">46-48</a>]. The large size and high GC content of the <em>COL4A5</em> gene render direct mutational analysis of genomic DNA technically difficult. In addition, the analysis of genomic DNA may not detect large gene rearrangements or splice-site mutations [<a href="#rid40">40,49</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other candidates for genetic testing</strong> – Other appropriate settings in which genetic testing may be beneficial include the following [<a href="#rid50">50</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prenatal diagnosis (due to family history of Alport syndrome)</p><p class="bulletIndent2"><span class="glyph">•</span>Confirmation or exclusion of the disorder in patients who cannot be unequivocally diagnosed by biopsy</p><p class="bulletIndent2"><span class="glyph">•</span>Absolute exclusion of the heterozygous state in an asymptomatic female</p><p class="bulletIndent2"><span class="glyph">•</span>When X-linked and autosomal disease cannot be differentiated by pedigree and immunohistochemical analysis</p><p></p><p class="bulletIndent1">In addition, genetic testing may also be appropriate for selected patients from the following groups if there is a suspicion for Alport syndrome:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Evaluation of persistent hematuria of undetermined etiology</p><p class="bulletIndent2"><span class="glyph">•</span>Genetic evaluation of patients with biopsy diagnosis of focal segmental glomerulosclerosis</p><p class="bulletIndent2"><span class="glyph">•</span>Genetic evaluation of patients with end-stage kidney disease of undetermined etiology</p><p></p><p>Current information on molecular testing for Alport syndrome can be obtained at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1116%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4trzEAfmGCQvouTQ5LbX9C3XVSHxjYdvs2mgciTuJx4IXLQ%3D%3D&amp;TOPIC_ID=6093" target="_blank">GeneReviews</a> and the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdatabases.lovd.nl%2Fshared%2Fgenes%23id%3D0%26order%3Did_%252CASC%26skip%5Bgeneid%5D%3Dgeneid%26FRMatchType_Genes%3D1%26FRMatchType_Genes%3D2%26FRMatchType_Genes%3D3%26FRReplaceAll_Genes%3D1%26%3DPreview%26%3DCancel%26%3DSubmit%26page_size%3D100%26page%3D37&amp;token=zaIvilKf1EvLilEPam0APogRtHHG2IUWzIM2UXADfZQB5O8sDoBhzLPQoLjFoCF7%2FdDWQ%2Bz%2Fwx%2BTYaTWOfif4cWxK3JWXKZz1uwQ5Z%2BkyauX3tlW8ne38IHhe%2BtFlX8jxZ3UietgudRlgnMyWAnFporwiGdG0f%2FRKU%2B6OkEHZVZ%2Fk3OhPCPnir5I%2FzKiOqQwDggskcaMIQlYPXKAt%2B1A9A%3D%3D&amp;TOPIC_ID=6093" target="_blank">Leiden Open Variation Database</a>. As molecular testing decreases in cost and increases in availability, the indications for such testing are likely to expand [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H3031370065"><span class="h2">Kidney and skin biopsy</span><span class="headingEndMark"> — </span>In a kidney biopsy specimen, the characteristic finding of longitudinal splitting of the lamina densa of the glomerular basement membrane (GBM) detected by electron microscopy is diagnostic for Alport syndrome  (<a class="graphic graphic_picture graphicRef68942 graphicRef79434" href="/z/d/graphic/68942.html" rel="external">picture 1A-B</a>). However, in young patients, this characteristic appearance of a laminated GBM may not be present. In males with X-linked Alport syndrome, for example, the proportion of GBM showing splitting increases from approximately 30 percent by age 10 to more than 90 percent by age 30 [<a href="#rid52">52</a>]. Attenuation of the GBM is common in young males with X-linked Alport syndrome, young and mature females with X-linked Alport syndrome, young males and females with autosomal recessive Alport syndrome, and patients with autosomal dominant Alport syndrome. (See  <a class="medical medical_review" href="/z/d/html/6086.html" rel="external">"Genetics, pathogenesis, and pathology of Alport syndrome (hereditary nephritis)", section on 'Histologic changes'</a>.)</p><p>If immunostaining for collagen IV is used and demonstrates absence or an abnormal distribution of the alpha-3, alpha-4 and/or alpha-5(IV) chains of the GBM, the diagnosis can be made in a patient with hematuria without the ultrastructural finding of a laminated GBM  (<a class="graphic graphic_figure graphicRef81373" href="/z/d/graphic/81373.html" rel="external">figure 2</a>). For example, immunostaining demonstrates absence of staining of the alpha-3, alpha-4, and alpha-5 (IV) chains in the GBM in approximately two-thirds of male patients and discontinuous distribution in many affected females with X-linked Alport syndrome. Bowman's capsules and distal tubule basement membranes may also show abnormal immunostaining for the alpha-3, alpha-4, and alpha-5 chains. (See  <a class="medical medical_review" href="/z/d/html/6086.html" rel="external">"Genetics, pathogenesis, and pathology of Alport syndrome (hereditary nephritis)", section on 'Immunostaining'</a>.)</p><p>A less invasive potential method to diagnose a child with suspected X-linked Alport syndrome is a skin biopsy using commercially available monoclonal antibody against the alpha-5(IV) chain  (<a class="graphic graphic_picture graphicRef72404" href="/z/d/graphic/72404.html" rel="external">picture 2</a>) [<a href="#rid2">2,50,53-56</a>] (see  <a class="medical medical_review" href="/z/d/html/6086.html" rel="external">"Genetics, pathogenesis, and pathology of Alport syndrome (hereditary nephritis)", section on 'Skin'</a>). If the protein is clearly absent in a male (or is clearly mosaic in a female), a diagnosis of X-linked Alport syndrome can be made and should be followed by molecular testing if available. If the test demonstrates normal expression of the alpha-5(IV) chain, then the patient has one of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>A variant in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F303630&amp;token=tEpDslnpc0F0kICl%2Fz7sFfZgq3tROP1vh4DhckKBw6GuDNPxjxwS5lxr5ffuoR0b&amp;TOPIC_ID=6093" target="_blank"><i>COL4A5</i></a> gene that permits deposition of a functionally abnormal but antigenically normal alpha-5(IV) chain, which occurs in approximately 30 percent of male patients with X-linked disease</p><p class="bulletIndent1"><span class="glyph">●</span>Autosomal Alport syndrome with abnormalities in either the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F120070&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1RjfaNRysdmhVCcBiOUYk1V&amp;TOPIC_ID=6093" target="_blank"><i>COL4A3</i></a> or <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F120131&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1TpD72nzlbuUDIfJV2QRuro&amp;TOPIC_ID=6093" target="_blank"><i>COL4A4</i></a> gene</p><p class="bulletIndent1"><span class="glyph">●</span>Another disorder</p><p></p><p>In these uncertain cases, the diagnosis of Alport syndrome can subsequently be confirmed or excluded by a kidney biopsy with analysis of collagen IV expression in the kidney or by molecular genetic testing. A kidney biopsy should also be performed if results of a skin biopsy are equivocal and a diagnosis is required because of signs of progressive kidney disease, such as hypertension, proteinuria, or elevated plasma creatinine concentration. (See  <a class="medical medical_review" href="/z/d/html/6086.html" rel="external">"Genetics, pathogenesis, and pathology of Alport syndrome (hereditary nephritis)", section on 'Skin'</a>.)</p><p>In up to 15 percent of cases, there is no identified family history of kidney disease [<a href="#rid25">25</a>] and the diagnosis is made by the presence of the characteristic lamination of the GBM, abnormal collagen IV immunostaining in skin or kidney, or identification of a pathogenic variant in <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F120070&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1RjfaNRysdmhVCcBiOUYk1V&amp;TOPIC_ID=6093" target="_blank"><i>COL4A3</i></a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F120131&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1TpD72nzlbuUDIfJV2QRuro&amp;TOPIC_ID=6093" target="_blank"><i>COL4A4</i></a>, or <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F303630&amp;token=tEpDslnpc0F0kICl%2Fz7sFfZgq3tROP1vh4DhckKBw6GuDNPxjxwS5lxr5ffuoR0b&amp;TOPIC_ID=6093" target="_blank"><i>COL4A5</i></a> by molecular genetic analysis. These cases may represent de novo variants in the <em>COL4A3</em>, <em>COL4A4</em>, or <em>COL4A5</em> genes or autosomal recessive disease [<a href="#rid57">57</a>].</p><p class="headingAnchor" id="H13"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Alport syndrome is typically differentiated from other major causes of persistent glomerular hematuria by a positive family history of hematuria associated with kidney failure and deafness. Other glomerular disorders that present in children with microscopic hematuria include IgA nephropathy, in which the family history is usually negative, and "thin basement membrane nephropathy" (TBMN), in which the family history may be positive for hematuria but kidney failure and deafness are typically absent or occur relatively late in life. However, some experts in the field including the author consider TBMN to be autosomal dominant Alport syndrome as these patients typically have a heterozygous variants in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F120070&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1RjfaNRysdmhVCcBiOUYk1V&amp;TOPIC_ID=6093" target="_blank"><i>COL4A3</i></a> or <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F120131&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1TpD72nzlbuUDIfJV2QRuro&amp;TOPIC_ID=6093" target="_blank"><i>COL4A4</i></a> genes [<a href="#rid1">1</a>]. In addition, a normal serum complement component 3 (C3) level differentiates patients with Alport syndrome from those with C3 glomerulonephropathy. (See  <a class="medical medical_review" href="/z/d/html/3038.html" rel="external">"Thin basement membrane nephropathy (benign familial hematuria)"</a> and <a class="local">'Diagnosis'</a> above and  <a class="medical medical_review" href="/z/d/html/3053.html" rel="external">"Isolated and persistent glomerular hematuria in adults"</a>.)</p><p>As noted above, the diagnosis of Alport syndrome is differentiated from other glomerular disease by confirmatory skin or kidney biopsy or molecular genetic testing. Alport syndrome is distinguished by the presence of the characteristic finding of lamination of the glomerular basement membrane (GBM) in samples from a kidney biopsy or abnormalities of collagen IV by immunostaining or by identification of pathogenic variant(s) in <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F120070&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1RjfaNRysdmhVCcBiOUYk1V&amp;TOPIC_ID=6093" target="_blank"><i>COL4A3</i></a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F120131&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1TpD72nzlbuUDIfJV2QRuro&amp;TOPIC_ID=6093" target="_blank"><i>COL4A4</i></a>, or <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F303630&amp;token=tEpDslnpc0F0kICl%2Fz7sFfZgq3tROP1vh4DhckKBw6GuDNPxjxwS5lxr5ffuoR0b&amp;TOPIC_ID=6093" target="_blank"><i>COL4A5</i></a>. As noted above, in this author's opinion, thin GBMs with or without focal segmental glomerulosclerosis in a patient with a <em>COL4A3</em>, <em>COL4A4</em>, or <em>COL4A5</em> variant is properly diagnosed as Alport syndrome.</p><p>Megathrombocytopenia (thrombocytopenia with large or giant platelets) has been described in some families with an autosomal dominant-transmitted glomerulopathy and sensorineural deafness. This complex has been referred to as Epstein syndrome, or Fechtner syndrome when associated with leukocyte cytoplasmic inclusions. These disorders have been mapped to chromosome 22 and result from variants in the gene encoding nonmuscle myosin heavy chain 9 (<em>MYH9</em>). Variants in this gene can also cause Sebastian syndrome, another giant platelet disorder, and nonsyndromic hereditary deafness. These disorders are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5921.html" rel="external">"Causes of thrombocytopenia in children", section on 'Large or giant platelets'</a>.)</p><p>Thus, Epstein and Fechtner syndromes represent distinct disorders arising from variants in noncollagen genes, not variants of autosomal dominant Alport syndrome. In some patients, ultrastructural changes reminiscent of Alport syndrome may be present. However, immunostaining for type IV collagen in patients with Epstein or Fechtner syndrome is normal.</p><p class="headingAnchor" id="H14"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>In patients who develop kidney failure, kidney transplantation is the preferred modality for kidney replacement therapy.</p><p>There is no specific treatment for Alport syndrome. However, there is evidence that the use of angiotensin antagonists is beneficial in slowing progression of kidney disease.</p><p class="headingAnchor" id="H1924595251"><span class="h2">Our approach</span><span class="headingEndMark"> — </span>Our management approach follows the consensus clinical practice recommendations for the treatment of Alport syndrome as developed and updated by the Alport Syndrome Research Collaborative [<a href="#rid58">58,59</a>]. It consists of the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring for kidney disease progression</strong> – Annual monitoring for microalbuminuria and proteinuria as soon as the diagnosis of Alport syndrome is made or beginning at one year of age for at-risk children.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Renin-angiotensin system (RAS) blockade</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>X-linked (males) and autosomal recessive disease</strong> – For male patients with X-linked Alport syndrome and for male and female patients with autosomal recessive Alport syndrome, angiotensin blockade therapy is provided at the time of diagnosis. If the diagnosis is made in infancy, treatment is withheld until the patient is between 12 and 24 months.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Implementation</strong> – The choice and dosing of agents are based on data from the ESCAPE and EARLY-PROTECT trials [<a href="#rid60">60,61</a>]. We prefer using a long-acting angiotensin converting enzyme inhibitor such as <a class="drug drug_general" data-topicid="9851" href="/z/d/drug information/9851.html" rel="external">ramipril</a> or <a class="drug drug_pediatric" data-topicid="12558" href="/z/d/drug information/12558.html" rel="external">lisinopril</a>, which require once-daily dosing.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For <a class="drug drug_general" data-topicid="9851" href="/z/d/drug information/9851.html" rel="external">ramipril</a>, an initial dose is prescribed of 1.6 mg/m<sup>2</sup>/day, which is increased over three to four months to a maximum dose of 6 mg/m<sup>2</sup>/day or until the maximum tolerated dose is reached.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For <a class="drug drug_pediatric" data-topicid="12558" href="/z/d/drug information/12558.html" rel="external">lisinopril</a>, an initial dose is prescribed of 0.2 mg/kg/day, which is increased to a maximum dose of 10 mg/day or until the maximum tolerated dose is reached.</p><p></p><p class="bulletIndent2">For pediatric patients, for both <a class="drug drug_general" data-topicid="9851" href="/z/d/drug information/9851.html" rel="external">ramipril</a> and <a class="drug drug_pediatric" data-topicid="12558" href="/z/d/drug information/12558.html" rel="external">lisinopril</a>, the dose should be adjusted as the child grows to maintain a constant dose based on weight.</p><p></p><p class="bulletIndent2">In the case of patients who are not yet exhibiting albuminuria or proteinuria at the time treatment is initiated, the escalation scheme is based on patient tolerance rather than urinary albumin or protein measurements.</p><p></p><p class="bulletIndent2">In patients who have proteinuria at the time of diagnosis, the same escalation strategy is used. (See  <a class="medical medical_review" href="/z/d/html/3101.html" rel="external">"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults", section on 'Issues with measuring urine albumin'</a> and <a class="local">'Phenotype-genotype correlation'</a> above.)</p><p></p><p class="bulletIndent2">If urine protein-creatinine ratio remains greater than 1.0 mg/mg despite maximal <a class="drug drug_general" data-topicid="9851" href="/z/d/drug information/9851.html" rel="external">ramipril</a> or <a class="drug drug_pediatric" data-topicid="12558" href="/z/d/drug information/12558.html" rel="external">lisinopril</a> dosing, dual angiotensin blockade with the addition of an angiotensin-receptor blocker can be considered. In a small group of pediatric patients, addition of <a class="drug drug_pediatric" data-topicid="13047" href="/z/d/drug information/13047.html" rel="external">losartan</a> at an initial dose of 0.8 mg/kg/day reduced urine protein levels by approximately 60 percent [<a href="#rid62">62</a>]. The addition of aldosterone inhibition to angiotensin blockade also reduced proteinuria in children with Alport syndrome, according to the findings of two small case series [<a href="#rid63">63,64</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Autosomal dominant disease</strong> <strong>and females with X-linked disease</strong> – In females with X-linked Alport syndrome and males and females with autosomal dominant Alport syndrome, angiotensin blockade therapy is initiated when the patient exhibits persistent microalbuminuria (urine microalbumin/creatinine ratio &gt;30 mg/g). We recommend using the same dosing protocols of <a class="drug drug_general" data-topicid="9851" href="/z/d/drug information/9851.html" rel="external">ramipril</a> and <a class="drug drug_pediatric" data-topicid="12558" href="/z/d/drug information/12558.html" rel="external">lisinopril</a> as in males with X-linked Alport syndrome. Effective contraception is mandatory for menstruating female patients to prevent fetopathy secondary to angiotensin blockade during pregnancy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Monitoring of patients receiving angiotensin blockade</strong> – We recommend serum electrolytes, kidney function, and urine albumin and/or protein measurement every six months in patients receiving angiotensin blockade therapy, with closer monitoring in patients with more advanced chronic kidney disease. In our experience, hyperkalemia is unusual among Alport syndrome patients treated with angiotensin blockade who have normal kidney function. For patients who develop hyperkalemia, management options include dietary potassium restriction, use of a potassium-chelating agent such as <a class="drug drug_pediatric" data-topicid="143556" href="/z/d/drug information/143556.html" rel="external">patiromer</a>, and reducing or discontinuing angiotensin blockade. (See  <a class="medical medical_review" href="/z/d/html/85908.html" rel="external">"Management of hyperkalemia in children", section on 'Chronic hyperkalemia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supportive</strong> <strong>care</strong> – Other supportive measures are initiated to prevent and treat complications of chronic kidney disease, which are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6085.html" rel="external">"Chronic kidney disease in children: Overview of management"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Kidney transplantation is the preferred option over dialysis for patients who develop kidney failure. There is a small, but not insignificant, risk of developing anti-glomerular basement membrane (anti-GBM) antibody disease in the allograft. (See <a class="local">'Anti-GBM antibody disease'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Supportive measures are used for hearing loss (eg, hearing aids) and ocular impairment as there are no interventions that correct hearing loss and ocular defects.</p><p></p><p class="headingAnchor" id="H15"><span class="h2">Renin-angiotensin blockade</span><span class="headingEndMark"> — </span>Several studies have demonstrated that RAS blockade therapy reduces proteinuria and diminishes the rate of glomerulosclerosis and disease progression in patients with Alport syndrome [<a href="#rid65">65-71</a>]. Additional data suggest that early RAS blockade therapy is beneficial and safe in patients who have microalbuminuria but who have not yet developed overt proteinuria [<a href="#rid60">60,71</a>]. As a result, the clinical practice recommendations from the Alport Syndrome Research Collaborative were updated to initiate earlier intervention [<a href="#rid59">59</a>]. These guidelines recommend initiation of RAS blockade at the time of diagnosis in males with X-linked Alport syndrome and males and females with autosomal recessive Alport syndrome, whether or not there is microalbuminuria or proteinuria, and in females with X-linked Alport syndrome and males and females with autosomal dominant Alport syndrome if there is persistent microalbuminuria. (See  <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6131.html" rel="external">"Nonemergent treatment of hypertension in children and adolescents", section on 'ACE inhibitors'</a> and  <a class="medical medical_review" href="/z/d/html/6131.html" rel="external">"Nonemergent treatment of hypertension in children and adolescents", section on 'Chronic kidney disease'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>In a large study of patients with Alport syndrome followed by the European Alport Registry for a mean duration of over 20 years, a retrospective analysis found that initiation of ACE inhibitors delayed dialysis in patients with proteinuria and normal kidney function compared with those who never received such therapy or who received treatment only when they developed impaired kidney function (dialysis initiated at a mean age of 40, 22, and 25 years, respectively) [<a href="#rid67">67</a>]. In a subsequent prospective report, RAS blockade therapy was also effective in preventing progression in kidney function deterioration for patients with autosomal or X-linked Alport syndrome with heterozygous mutations in type IV collagen genes [<a href="#rid69">69</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a large retrospective study of Japanese patients with X-linked disease, treatment with RAS blockade therapy was associated with a delay in the onset of kidney failure (previously referred to end-stage kidney disease) [<a href="#rid70">70</a>]. Exposure to RAS blockade therapy versus no exposure delayed kidney failure with both truncating (median age 28 versus 16 years) and nontruncating mutations (median age 50 versus 33 years).</p><p></p><p class="headingAnchor" id="H111104511"><span class="h2">Other drugs (not recommended)</span></p><p class="headingAnchor" id="H16"><span class="h3">Cyclosporine</span><span class="headingEndMark"> — </span>Data are inconclusive regarding the benefit of <a class="drug drug_pediatric" data-topicid="13193" href="/z/d/drug information/13193.html" rel="external">cyclosporine</a> to improve kidney survival, and cyclosporine is associated with nephrotoxicity. As a result, until further data demonstrate benefit from cyclosporine therapy, we do not suggest that this agent be used in patients with Alport syndrome to slow the progression of kidney disease.</p><p>In humans, uncontrolled studies of <a class="drug drug_pediatric" data-topicid="13193" href="/z/d/drug information/13193.html" rel="external">cyclosporine</a> therapy have produced divergent results. In a Spanish study of eight patients who ranged in age from 15 to 27 years of age at follow-up, serum creatinine values remained stable compared with pretreatment measurements after a mean duration of cyclosporine therapy of 8.4 years [<a href="#rid72">72</a>]. In addition, patients had either a lower or equivalent degree of proteinuria compared with baseline values. In contrast, a study of nine French patients reported that cyclosporine therapy suppressed proteinuria but reduced glomerular filtration rate and possibly accelerated renal fibrosis [<a href="#rid73">73</a>]. In an uncontrolled study of Italian children with Alport syndrome, cyclosporine therapy transiently reduced proteinuria but did not prevent subsequent decline in kidney function [<a href="#rid74">74</a>].</p><p>In a canine model of X-linked Alport syndrome, <a class="drug drug_pediatric" data-topicid="13193" href="/z/d/drug information/13193.html" rel="external">cyclosporine</a> treatment failed to diminish proteinuria but resulted in longer kidney survival [<a href="#rid75">75</a>].</p><p class="headingAnchor" id="H2467925260"><span class="h3">SGL2 inhibition</span><span class="headingEndMark"> — </span>The possible role of sodium glucose-like cotransporter-2 (SGL2) inhibition in Alport syndrome is uncertain due to a paucity of relevant data [<a href="#rid76">76</a>]. Although a two-year, double-blind, placebo-controlled, randomized trial of bardoxolone therapy found higher estimated glomerular filtration rates in treated patients, bardoxolone has not been approved by the US Food and Drug Administration for treatment of Alport syndrome, due to concerns regarding safety and the significance of the effect on estimated glomerular filtration rate [<a href="#rid77">77</a>].</p><p class="headingAnchor" id="H17"><span class="h2">Kidney transplantation</span><span class="headingEndMark"> — </span>Patients with Alport syndrome typically have excellent kidney transplant outcomes. Recurrent disease does not occur in the transplanted graft, because the donor kidney has a normal GBM. However, anti-GBM antibody disease (anti-GBM antibody disease) occurs in approximately 3 percent of affected males who receive transplants.</p><p class="headingAnchor" id="H18"><span class="h3">Anti-GBM antibody disease</span><span class="headingEndMark"> — </span>Because the incidence of clinical anti-GBM antibody disease is low, kidney transplantation is <strong>not</strong> contraindicated in patients with Alport syndrome [<a href="#rid42">42</a>]. De novo anti-GBM antibody disease (also referred to as Alport post-transplant nephritis) develops in approximately 3 percent of transplanted males [<a href="#rid17">17,25,53,78-84</a>]. In males with X-linked disease, antibodies are directed primarily against the alpha-5(IV) chain, but antibodies against the alpha-3(IV) chain are also found in some patients [<a href="#rid27">27,78,81,84-86</a>]. In patients with autosomal recessive Alport syndrome who develop Alport post-transplant nephritis, the predominant target of anti-GBM antibodies is the alpha-3(IV) chain [<a href="#rid86">86,87</a>]. Patients with autosomal dominant Alport syndrome do not appear to be at increased risk for de novo anti-GBM disease after kidney transplantation.</p><p>The vast majority of cases of Alport post-transplant nephritis occur in males. This is consistent with the hypothesis that even a female heterozygote who developed kidney failure would have some cells synthesizing and secreting a normal alpha-5(IV) chain; thus, a transplanted kidney would not be expressing a new antigenic epitope to these patients. However, Alport post-transplant nephritis has been described in females with autosomal recessive disease [<a href="#rid87">87,88</a>]. In these patients, the anti-GBM antibodies are directed primarily against the alpha-3(IV) chain.</p><p>Although anti-GBM antibody disease usually occurs in the first year after transplantation, an interval of several years between transplantation and presentation with Alport post-transplant nephritis can occur [<a href="#rid53">53</a>]. Affected patients typically have circulating anti-GBM antibodies, and up to three-quarters of patients may develop crescentic glomerulonephritis and loss of the graft [<a href="#rid53">53,79,80</a>].</p><p>The key to early diagnosis of Alport post-transplant nephritis is a low threshold for obtaining an allograft biopsy with immunofluorescence, which demonstrates the characteristic finding of linear deposition of IgG along the glomerular capillaries and, occasionally, the distal tubules. The clinician should not rely solely on commercial anti-GBM assays, because they are optimized for detection of antibodies directed against the Goodpasture antigen rather than antibodies against the alpha-5(IV) chain. (See  <a class="medical medical_review" href="/z/d/html/3108.html" rel="external">"Anti-GBM (Goodpasture) disease: Pathogenesis, clinical manifestations, and diagnosis", section on 'Evaluation and diagnosis'</a>.)</p><p>Plasmapheresis and immunosuppression with <a class="drug drug_pediatric" data-topicid="12601" href="/z/d/drug information/12601.html" rel="external">methylprednisolone</a> and <a class="drug drug_pediatric" data-topicid="13191" href="/z/d/drug information/13191.html" rel="external">cyclophosphamide</a>, which are initially used in treating primary anti-GBM disease, have been of <strong>limited</strong> benefit in post-transplant disease but may be helpful [<a href="#rid53">53</a>]. In our center, we treat patients with primary anti-GBM disease with a combination of plasmapheresis and cyclophosphamide. Retransplantation in these patients is associated with a high risk of recurrence (seven of eight in one report) [<a href="#rid53">53</a>]. (See  <a class="medical medical_review" href="/z/d/html/3085.html" rel="external">"Anti-GBM (Goodpasture) disease: Treatment and prognosis"</a>.)</p><p>The optimal management in patients who lost their first graft to Alport post-transplant nephritis and whether a second transplant should be performed are uncertain. The recurrence rate is high in subsequent transplants [<a href="#rid43">43,85</a>], but isolated cases of successful retransplantation have been reported [<a href="#rid79">79</a>].</p><p>It is unclear why only some patients develop anti-GBM antibody disease after transplantation. In patients with X-linked disease, the specific type of mutation may be an important factor in developing anti-GBM antibody disease. The risk appears to be greatest in patients with <em>COL4A5</em> variants that prevent synthesis of the alpha-5(IV) chain [<a href="#rid80">80,82,85</a>]. This was illustrated in one review of Alport patients with post-transplant anti-GBM disease that reported 54 percent (7 of 13) of patients with anti-GBM disease had large deletions in the <em>COL4A5</em> gene compared with a deletion frequency of 16 percent in all patients with Alport syndrome [<a href="#rid82">82</a>].</p><p>However, a <em>COL4A5</em> gene deletion alone does not appear to be sufficient to cause anti-GBM disease following kidney transplantation. In one study, only one of seven patients with a <em>COL4A5</em> deletion and complete absence of the alpha-5(IV) chain developed anti-GBM disease in the kidney transplant [<a href="#rid27">27</a>], suggesting that factors other than exposure to a previously unseen antigen must be involved. The complex interplay between the host's underlying gene defect, immune response factors such as antigen presentation, and immunosuppression are all factors that must be considered in the development of post-transplant anti-GBM disease [<a href="#rid89">89</a>].</p><p>Differences in the ability to activate the cellular arm of the immune system may be another reason why only some patients develop Alport post-transplant nephritis. One study evaluated the variation in anti-GBM antibody formation in patients with Alport syndrome in whom post-transplant disease had or had not developed (12 and 10 patients, respectively) [<a href="#rid41">41</a>]. All patients in both groups displayed some combination of antibodies directed against the alpha 3, 4, or 5 chains of collagen IV, and the pattern of antibody expression did not differ between the two groups. It has also been noted that some Alport patients develop linear immunoglobulin G (IgG) staining of the transplant GBM, without concomitant evidence of complement component 3 (C3) deposition, glomerulonephritis, or allograft dysfunction [<a href="#rid79">79</a>]. These data suggest that nonhumoral immune factors contribute to the variation in the frequency of anti-GBM disease post-transplant.</p><p class="headingAnchor" id="H23922467"><span class="h3">Living-related donors</span><span class="headingEndMark"> — </span>Since Alport syndrome is a familial disorder, potential living-related kidney donors for Alport patients must be carefully evaluated [<a href="#rid90">90-92</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Male relatives of a patient with X-linked Alport syndrome who do not have hematuria are suitable candidates.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Females who are heterozygous for X-linked Alport syndrome should <strong>not</strong> be a donor unless:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>They are asymptomatic without evidence of hematuria (approximately 5 percent of individuals) and understand and accept that there is a 50 percent risk of transmitting the <em>COL4A5</em> variant with each pregnancy. This would mean that if they donate a kidney to a male relative prior to childbearing, the female could not subsequently be a donor to an affected son.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>They are over 45 years of age with normal urine protein excretion, normal hearing by audiogram, and normal kidney function. However, they would be donors of last resort.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Males and females who are heterozygous for a <em>COL4A3</em> or <em>COL4A4</em> variants may be suitable donors to a recipient with autosomal recessive Alport syndrome if they have normal urine protein excretion and kidney function. However, if the heterozygous state is associated with chronic kidney disease or kidney failure, donation would not be advisable.</p><p></p><p class="headingAnchor" id="H19"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics</strong> – Alport syndrome is a genetically heterogeneous disease that results from mutations in genes encoding the alpha-3, alpha-4, and alpha-5(IV) chains of collagen IV and that can be transmitted in a X-linked, autosomal recessive, or autosomal dominant fashion. (See <a class="local">'Genetics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The abnormal chains of collagen IV cause basement membrane impairment in the glomerulus, eye, and inner ear, resulting in the clinical findings of Alport syndrome.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The classical presentation of Alport syndrome is based on clinical manifestations of affected males with X-linked disease. These features include glomerular disease that progresses to kidney failure, ocular abnormalities (eg, anterior lenticonus), sensorineural hearing loss, and positive family history of kidney failure and hearing loss.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with autosomal recessive disease have a similar clinical presentation and course as those with X-linked disease, whereas patients with autosomal dominant disease generally have a slower deterioration of kidney function and are less likely to exhibit sensorineural deafness and ocular abnormalities. (See <a class="local">'Clinical manifestations and course'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The initial kidney manifestation of Alport syndrome is usually asymptomatic microscopic hematuria. Gross hematuria may also be a presenting finding, which may occur after an upper respiratory infection. The serum creatinine and blood pressure are normal in early childhood, but progressive insufficiency, hypertension, and increasing proteinuria develop with time. Kidney failure usually occurs in affected males with X-linked disease between the ages of 16 and 35, but the course is more indolent in some families. (See <a class="local">'Kidney manifestations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Females with X-linked Alport syndrome are heterozygous for the <em>COL4A5</em> gene variant and have a range of clinical findings due to lyonization, in which only one X chromosome is active per cell. (See <a class="local">'Phenotype-genotype correlation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of Alport syndrome is made by molecular genetic analysis (preferred if cost is not an issue) or skin or kidney biopsy with characteristic findings of Alport syndrome  (<a class="graphic graphic_algorithm graphicRef115552" href="/z/d/graphic/115552.html" rel="external">algorithm 1</a>). (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – (See <a class="local">'Our approach'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>There is no specific treatment to correct the underlying defect for Alport syndrome.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with Alport disease and overt proteinuria, angiotensin blockade therapy reduces the rate of protein excretion and appears to slow the progression of the disease. As a result, annual monitoring for microalbuminuria and proteinuria is performed as soon as Alport syndrome is diagnosed.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest early renin-angiotensin system (RAS) blockade for patients with Alport disease either with an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB) (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Renin-angiotensin blockade'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We do <strong>not</strong> suggest <a class="drug drug_pediatric" data-topicid="13193" href="/z/d/drug information/13193.html" rel="external">cyclosporine</a> therapy in patients with Alport syndrome (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Cyclosporine has not been shown to reduce the rate of kidney disease progression and has significant side effects including cyclosporine toxicity. (See <a class="local">'Cyclosporine'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who develop kidney failure, the preferred modality of kidney replacement therapy is kidney transplantation. Recurrent disease does not occur in the transplant (since the donor glomerular basement membrane [GBM] is normal); however, approximately 3 percent of transplanted males develop de novo anti-GBM antibody disease. (See <a class="local">'Kidney transplantation'</a> above and <a class="local">'Anti-GBM antibody disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Supportive measures are used for hearing loss (eg, hearing aids) and ocular impairment in affected patients.</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kashtan CE, Ding J, Garosi G, et al. Alport syndrome: a unified classification of genetic disorders of collagen IV α345: a position paper of the Alport Syndrome Classification Working Group. Kidney Int 2018; 93:1045.</a></li><li><a class="nounderline abstract_t">Kashtan CE. Alport syndrome. An inherited disorder of renal, ocular, and cochlear basement membranes. Medicine (Baltimore) 1999; 78:338.</a></li><li><a class="nounderline abstract_t">Waldherr R. Familial glomerular disease. Contrib Nephrol 1982; 33:104.</a></li><li><a class="nounderline abstract_t">Trachtman H, Weiss RA, Bennett B, Greifer I. Isolated hematuria in children: indications for a renal biopsy. Kidney Int 1984; 25:94.</a></li><li><a class="nounderline abstract_t">Coppo R, Gianoglio B, Porcellini MG, Maringhini S. Frequency of renal diseases and clinical indications for renal biopsy in children (report of the Italian National Registry of Renal Biopsies in Children). Group of Renal Immunopathology of the Italian Society of Pediatric Nephrology and Group of Renal Immunopathology of the Italian Society of Nephrology. Nephrol Dial Transplant 1998; 13:293.</a></li><li><a class="nounderline abstract_t">Hasstedt SJ, Atkin CL. X-linked inheritance of Alport syndrome: family P revisited. Am J Hum Genet 1983; 35:1241.</a></li><li><a class="nounderline abstract_t">Persson U, Hertz JM, Wieslander J, Segelmark M. Alport syndrome in southern Sweden. Clin Nephrol 2005; 64:85.</a></li><li><a class="nounderline abstract_t">Gibson J, Fieldhouse R, Chan MMY, et al. Prevalence Estimates of Predicted Pathogenic COL4A3-COL4A5 Variants in a Population Sequencing Database and Their Implications for Alport Syndrome. J Am Soc Nephrol 2021; 32:2273.</a></li><li><a class="nounderline abstract_t">Pochet JM, Bobrie G, Landais P, et al. Renal prognosis in Alport's and related syndromes: influence of the mode of inheritance. Nephrol Dial Transplant 1989; 4:1016.</a></li><li><a class="nounderline abstract_t">Marcocci E, Uliana V, Bruttini M, et al. Autosomal dominant Alport syndrome: molecular analysis of the COL4A4 gene and clinical outcome. Nephrol Dial Transplant 2009; 24:1464.</a></li><li><a class="nounderline abstract_t">Gubler M, Levy M, Broyer M, et al. Alport's syndrome. A report of 58 cases and a review of the literature. Am J Med 1981; 70:493.</a></li><li><a class="nounderline abstract_t">Gubler MC. Inherited diseases of the glomerular basement membrane. Nat Clin Pract Nephrol 2008; 4:24.</a></li><li><a class="nounderline abstract_t">Izzedine H, Tankere F, Launay-Vacher V, Deray G. Ear and kidney syndromes: molecular versus clinical approach. Kidney Int 2004; 65:369.</a></li><li><a class="nounderline abstract_t">Barozzi S, Soi D, Intieri E, et al. Vestibular and audiological findings in the Alport syndrome. Am J Med Genet A 2020; 182:2345.</a></li><li><a class="nounderline abstract_t">Grünfeld JP. The clinical spectrum of hereditary nephritis. Kidney Int 1985; 27:83.</a></li><li><a class="nounderline abstract_t">Shaw EA, Colville D, Wang YY, et al. Characterization of the peripheral retinopathy in X-linked and autosomal recessive Alport syndrome. Nephrol Dial Transplant 2007; 22:104.</a></li><li><a class="nounderline abstract_t">Byrne MC, Budisavljevic MN, Fan Z, et al. Renal transplant in patients with Alport's syndrome. Am J Kidney Dis 2002; 39:769.</a></li><li><a class="nounderline abstract_t">Perrin D, Jungers P, Grünfeld JP, et al. Perimacular changes in Alport's syndrome. Clin Nephrol 1980; 13:163.</a></li><li><a class="nounderline abstract_t">Shah SN, Weinberg DV. Giant macular hole in Alport syndrome. Ophthalmic Genet 2010; 31:94.</a></li><li><a class="nounderline abstract_t">Dahan K, Heidet L, Zhou J, et al. Smooth muscle tumors associated with X-linked Alport syndrome: carrier detection in females. Kidney Int 1995; 48:1900.</a></li><li><a class="nounderline abstract_t">Uliana V, Marcocci E, Mucciolo M, et al. Alport syndrome and leiomyomatosis: the first deletion extending beyond COL4A6 intron 2. Pediatr Nephrol 2011; 26:717.</a></li><li><a class="nounderline abstract_t">Vaicys C, Hunt CD, Heary RF. Ruptured intracranial aneurysm in an adolescent with Alport's syndrome--a new expression of type IV collagenopathy: case report. Surg Neurol 2000; 54:68.</a></li><li><a class="nounderline abstract_t">Lyons OT, St John ER, Morales JP, et al. Ruptured thoracoabdominal aortic aneurysm in a renal transplant patient with Alport's syndrome. Ann Vasc Surg 2007; 21:816.</a></li><li><a class="nounderline abstract_t">Kashtan CE, Segal Y, Flinter F, et al. Aortic abnormalities in males with Alport syndrome. Nephrol Dial Transplant 2010; 25:3554.</a></li><li><a class="nounderline abstract_t">Tryggvason K, Zhou J, Hostikka SL, Shows TB. Molecular genetics of Alport syndrome. Kidney Int 1993; 43:38.</a></li><li><a class="nounderline abstract_t">Barker DF, Hostikka SL, Zhou J, et al. Identification of mutations in the COL4A5 collagen gene in Alport syndrome. Science 1990; 248:1224.</a></li><li><a class="nounderline abstract_t">Antignac C, Knebelmann B, Drouot L, et al. Deletions in the COL4A5 collagen gene in X-linked Alport syndrome. Characterization of the pathological transcripts in nonrenal cells and correlation with disease expression. J Clin Invest 1994; 93:1195.</a></li><li><a class="nounderline abstract_t">Jais JP, Knebelmann B, Giatras I, et al. X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males. J Am Soc Nephrol 2000; 11:649.</a></li><li><a class="nounderline abstract_t">Bekheirnia MR, Reed B, Gregory MC, et al. Genotype-phenotype correlation in X-linked Alport syndrome. J Am Soc Nephrol 2010; 21:876.</a></li><li><a class="nounderline abstract_t">Jais JP, Knebelmann B, Giatras I, et al. X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a "European Community Alport Syndrome Concerted Action" study. J Am Soc Nephrol 2003; 14:2603.</a></li><li><a class="nounderline abstract_t">Grünfeld JP, Noël LH, Hafez S, Droz D. Renal prognosis in women with hereditary nephritis. Clin Nephrol 1985; 23:267.</a></li><li><a class="nounderline abstract_t">Kashtan CE. Alport syndrome and the X chromosome: implications of a diagnosis of Alport syndrome in females. Nephrol Dial Transplant 2007; 22:1499.</a></li><li><a class="nounderline abstract_t">Goka S, Copelovitch L, Levy Erez D. Long-term outcome among females with Alport syndrome from a single pediatric center. Pediatr Nephrol 2021; 36:945.</a></li><li><a class="nounderline abstract_t">Matthaiou A, Poulli T, Deltas C. Prevalence of clinical, pathological and molecular features of glomerular basement membrane nephropathy caused by COL4A3 or COL4A4 mutations: a systematic review. Clin Kidney J 2020; 13:1025.</a></li><li><a class="nounderline abstract_t">Solanki KV, Hu Y, Moore BS, et al. The Phenotypic Spectrum of COL4A3 Heterozygotes. medRxiv 2023.</a></li><li><a class="nounderline abstract_t">Vitelli F, Piccini M, Caroli F, et al. Identification and characterization of a highly conserved protein absent in the Alport syndrome (A), mental retardation (M), midface hypoplasia (M), and elliptocytosis (E) contiguous gene deletion syndrome (AMME). Genomics 1999; 55:335.</a></li><li><a class="nounderline abstract_t">Pirson Y. Making the diagnosis of Alport's syndrome. Kidney Int 1999; 56:760.</a></li><li><a class="nounderline abstract_t">Martin P, Heiskari N, Zhou J, et al. High mutation detection rate in the COL4A5 collagen gene in suspected Alport syndrome using PCR and direct DNA sequencing. J Am Soc Nephrol 1998; 9:2291.</a></li><li><a class="nounderline abstract_t">Inoue Y, Nishio H, Shirakawa T, et al. Detection of mutations in the COL4A5 gene in over 90% of male patients with X-linked Alport's syndrome by RT-PCR and direct sequencing. Am J Kidney Dis 1999; 34:854.</a></li><li><a class="nounderline abstract_t">King K, Flinter FA, Green PM. A two-tier approach to mutation detection in the COL4A5 gene for Alport syndrome. Hum Mutat 2006; 27:1061.</a></li><li><a class="nounderline abstract_t">Kalluri R, Werner MC, Zamborsky ED, et al. Identification of alpha 3, alpha 4, and alpha 5 chains of type IV collagen as the primary target for the alport post-transplant anti-GBM alloantibodies (abstract). J Am Soc Nephrol 1997; 8:498A.</a></li><li><a class="nounderline abstract_t">Göbel J, Olbricht CJ, Offner G, et al. Kidney transplantation in Alport's syndrome: long-term outcome and allograft anti-GBM nephritis. Clin Nephrol 1992; 38:299.</a></li><li><a class="nounderline abstract_t">Browne G, Brown PA, Tomson CR, et al. Retransplantation in Alport post-transplant anti-GBM disease. Kidney Int 2004; 65:675.</a></li><li><a class="nounderline abstract_t">King K, Flinter FA, Nihalani V, Green PM. Unusual deep intronic mutations in the COL4A5 gene cause X linked Alport syndrome. Hum Genet 2002; 111:548.</a></li><li><a class="nounderline abstract_t">Tazón-Vega B, Ars E, Burset M, et al. Genetic testing for X-linked Alport syndrome by direct sequencing of COL4A5 cDNA from hair root RNA samples. Am J Kidney Dis 2007; 50:257.e1.</a></li><li><a class="nounderline abstract_t">Fallerini C, Dosa L, Tita R, et al. Unbiased next generation sequencing analysis confirms the existence of autosomal dominant Alport syndrome in a relevant fraction of cases. Clin Genet 2014; 86:252.</a></li><li><a class="nounderline abstract_t">Morinière V, Dahan K, Hilbert P, et al. Improving mutation screening in familial hematuric nephropathies through next generation sequencing. J Am Soc Nephrol 2014; 25:2740.</a></li><li><a class="nounderline abstract_t">Savige J, Ariani F, Mari F, et al. Expert consensus guidelines for the genetic diagnosis of Alport syndrome. Pediatr Nephrol 2019; 34:1175.</a></li><li><a class="nounderline abstract_t">Arrondel C, Deschênes G, Le Meur Y, et al. A large tandem duplication within the COL4A5 gene is responsible for the high prevalence of Alport syndrome in French Polynesia. Kidney Int 2004; 65:2030.</a></li><li><a class="nounderline abstract_t">Kashtan CE. Alport syndrome: is diagnosis only skin-deep? Kidney Int 1999; 55:1575.</a></li><li><a class="nounderline abstract_t">Savige J, Lipska-Zietkiewicz BS, Watson E, et al. Guidelines for Genetic Testing and Management of Alport Syndrome. Clin J Am Soc Nephrol 2022; 17:143.</a></li><li><a class="nounderline abstract_t">Rumpelt HJ. Hereditary nephropathy (Alport syndrome): correlation of clinical data with glomerular basement membrane alterations. Clin Nephrol 1980; 13:203.</a></li><li><a class="nounderline abstract_t">Kashtan CE, Michael AF. Alport syndrome. Kidney Int 1996; 50:1445.</a></li><li><a class="nounderline abstract_t">Massella L, Onetti Muda A, Faraggiana T, et al. Epidermal basement membrane alpha 5(IV) expression in females with Alport syndrome and severity of renal disease. Kidney Int 2003; 64:1787.</a></li><li><a class="nounderline abstract_t">Yoshioka K, Hino S, Takemura T, et al. Type IV collagen alpha 5 chain. Normal distribution and abnormalities in X-linked Alport syndrome revealed by monoclonal antibody. Am J Pathol 1994; 144:986.</a></li><li><a class="nounderline abstract_t">van der Loop FT, Monnens LA, Schröder CH, et al. Identification of COL4A5 defects in Alport's syndrome by immunohistochemistry of skin. Kidney Int 1999; 55:1217.</a></li><li><a class="nounderline abstract_t">Kitagawa K, Nakanishi K, Iijima K, et al. Mutation in alpha 5(IV) collagen chain gene in nonfamilial hematuria. J Am Soc Nephrol 1995; 6:264.</a></li><li><a class="nounderline abstract_t">Kashtan CE, Ding J, Gregory M, et al. Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative. Pediatr Nephrol 2013; 28:5.</a></li><li><a class="nounderline abstract_t">Kashtan CE, Gross O. Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults-an update for 2020. Pediatr Nephrol 2021; 36:711.</a></li><li><a class="nounderline abstract_t">Gross O, Tönshoff B, Weber LT, et al. A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport's syndrome. Kidney Int 2020; 97:1275.</a></li><li><a class="nounderline abstract_t">ESCAPE Trial Group, Wühl E, Trivelli A, et al. Strict blood-pressure control and progression of renal failure in children. N Engl J Med 2009; 361:1639.</a></li><li><a class="nounderline abstract_t">Seeman T, Pohl M, Misselwitz J, John U. Angiotensin receptor blocker reduces proteinuria independently of blood pressure in children already treated with Angiotensin-converting enzyme inhibitors. Kidney Blood Press Res 2009; 32:440.</a></li><li><a class="nounderline abstract_t">Giani M, Mastrangelo A, Villa R, et al. Alport syndrome: the effects of spironolactone on proteinuria and urinary TGF-β1. Pediatr Nephrol 2013; 28:1837.</a></li><li><a class="nounderline abstract_t">Kaito H, Nozu K, Iijima K, et al. The effect of aldosterone blockade in patients with Alport syndrome. Pediatr Nephrol 2006; 21:1824.</a></li><li><a class="nounderline abstract_t">Proesmans W, Van Dyck M. Enalapril in children with Alport syndrome. Pediatr Nephrol 2004; 19:271.</a></li><li><a class="nounderline abstract_t">Webb NJ, Lam C, Shahinfar S, et al. Efficacy and safety of losartan in children with Alport syndrome--results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial. Nephrol Dial Transplant 2011; 26:2521.</a></li><li><a class="nounderline abstract_t">Gross O, Licht C, Anders HJ, et al. Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int 2012; 81:494.</a></li><li><a class="nounderline abstract_t">Zhang Y, Wang F, Ding J, et al. Long-term treatment by ACE inhibitors and angiotensin receptor blockers in children with Alport syndrome. Pediatr Nephrol 2016; 31:67.</a></li><li><a class="nounderline abstract_t">Stock J, Kuenanz J, Glonke N, et al. Prospective study on the potential of RAAS blockade to halt renal disease in Alport syndrome patients with heterozygous mutations. Pediatr Nephrol 2017; 32:131.</a></li><li><a class="nounderline abstract_t">Yamamura T, Horinouchi T, Nagano C, et al. Genotype-phenotype correlations influence the response to angiotensin-targeting drugs in Japanese patients with male X-linked Alport syndrome. Kidney Int 2020; 98:1605.</a></li><li><a class="nounderline abstract_t">Zhang Y, Böckhaus J, Wang F, et al. Genotype-phenotype correlations and nephroprotective effects of RAAS inhibition in patients with autosomal recessive Alport syndrome. Pediatr Nephrol 2021; 36:2719.</a></li><li><a class="nounderline abstract_t">Callís L, Vila A, Carrera M, Nieto J. Long-term effects of cyclosporine A in Alport's syndrome. Kidney Int 1999; 55:1051.</a></li><li><a class="nounderline abstract_t">Charbit M, Gubler MC, Dechaux M, et al. Cyclosporin therapy in patients with Alport syndrome. Pediatr Nephrol 2007; 22:57.</a></li><li><a class="nounderline abstract_t">Massella L, Muda AO, Legato A, et al. Cyclosporine A treatment in patients with Alport syndrome: a single-center experience. Pediatr Nephrol 2010; 25:1269.</a></li><li><a class="nounderline abstract_t">Chen D, Jefferson B, Harvey SJ, et al. Cyclosporine a slows the progressive renal disease of alport syndrome (X-linked hereditary nephritis): results from a canine model. J Am Soc Nephrol 2003; 14:690.</a></li><li><a class="nounderline abstract_t">Boeckhaus J, Gross O. Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Hereditary Podocytopathies, Alport Syndrome, and FSGS: A Case Series to Better Plan a Large-Scale Study. Cells 2021; 10.</a></li><li><a class="nounderline abstract_t">Warady BA, Pergola PE, Agarwal R, et al. Effects of Bardoxolone Methyl in Alport Syndrome. Clin J Am Soc Nephrol 2022; 17:1763.</a></li><li><a class="nounderline abstract_t">Hudson BG, Kalluri R, Gunwar S, et al. The pathogenesis of Alport syndrome involves type IV collagen molecules containing the alpha 3(IV) chain: evidence from anti-GBM nephritis after renal transplantation. Kidney Int 1992; 42:179.</a></li><li><a class="nounderline abstract_t">Quérin S, Noël LH, Grünfeld JP, et al. Linear glomerular IgG fixation in renal allografts: incidence and significance in Alport's syndrome. Clin Nephrol 1986; 25:134.</a></li><li><a class="nounderline abstract_t">Kashtan CE, Butkowski RJ, Kleppel MM, et al. Posttransplant anti-glomerular basement membrane nephritis in related males with Alport syndrome. J Lab Clin Med 1990; 116:508.</a></li><li><a class="nounderline abstract_t">Kalluri R, Weber M, Netzer KO, et al. COL4A5 gene deletion and production of post-transplant anti-alpha 3(IV) collagen alloantibodies in Alport syndrome. Kidney Int 1994; 45:721.</a></li><li><a class="nounderline abstract_t">Ding J, Zhou J, Tryggvason K, Kashtan CE. COL4A5 deletions in three patients with Alport syndrome and posttransplant antiglomerular basement membrane nephritis. J Am Soc Nephrol 1994; 5:161.</a></li><li><a class="nounderline abstract_t">Shah B, First MR, Mendoza NC, et al. Alport's syndrome: risk of glomerulonephritis induced by anti-glomerular-basement-membrane antibody after renal transplantation. Nephron 1988; 50:34.</a></li><li><a class="nounderline abstract_t">Hellmark T, Johansson C, Wieslander J. Characterization of anti-GBM antibodies involved in Goodpasture's syndrome. Kidney Int 1994; 46:823.</a></li><li><a class="nounderline abstract_t">Heiskari N, Zhang X, Zhou J, et al. Identification of 17 mutations in ten exons in the COL4A5 collagen gene, but no mutations found in four exons in COL4A6: a study of 250 patients with hematuria and suspected of having Alport syndrome. J Am Soc Nephrol 1996; 7:702.</a></li><li><a class="nounderline abstract_t">Brainwood D, Kashtan C, Gubler MC, Turner AN. Targets of alloantibodies in Alport anti-glomerular basement membrane disease after renal transplantation. Kidney Int 1998; 53:762.</a></li><li><a class="nounderline abstract_t">Kalluri R, van den Heuvel LP, Smeets HJ, et al. A COL4A3 gene mutation and post-transplant anti-alpha 3(IV) collagen alloantibodies in Alport syndrome. Kidney Int 1995; 47:1199.</a></li><li><a class="nounderline abstract_t">Ding J, Stitzel J, Berry P, et al. Autosomal recessive Alport syndrome: mutation in the COL4A3 gene in a woman with Alport syndrome and posttransplant antiglomerular basement membrane nephritis. J Am Soc Nephrol 1995; 5:1714.</a></li><li><a class="nounderline abstract_t">Wang XP, Fogo AB, Colon S, et al. Distinct epitopes for anti-glomerular basement membrane alport alloantibodies and goodpasture autoantibodies within the noncollagenous domain of alpha3(IV) collagen: a janus-faced antigen. J Am Soc Nephrol 2005; 16:3563.</a></li><li><a class="nounderline abstract_t">Kashtan CE. Renal transplantation in patients with Alport syndrome. Pediatr Transplant 2006; 10:651.</a></li><li><a class="nounderline abstract_t">Gross O, Weber M, Fries JW, Müller GA. Living donor kidney transplantation from relatives with mild urinary abnormalities in Alport syndrome: long-term risk, benefit and outcome. Nephrol Dial Transplant 2009; 24:1626.</a></li><li><a class="nounderline abstract_t">Kashtan CE. Women with Alport syndrome: risks and rewards of kidney donation. Nephrol Dial Transplant 2009; 24:1369.</a></li></ol></div><div id="topicVersionRevision">Topic 6093 Version 45.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29551517" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Alport syndrome: a unified classification of genetic disorders of collagen IVα345: a position paper of the Alport Syndrome Classification Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10499074" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Alport syndrome. An inherited disorder of renal, ocular, and cochlear basement membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6749416" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Familial glomerular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6727131" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Isolated hematuria in children: indications for a renal biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9509437" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Frequency of renal diseases and clinical indications for renal biopsy in children (report of the Italian National Registry of Renal Biopsies in Children). Group of Renal Immunopathology of the Italian Society of Pediatric Nephrology and Group of Renal Immunopathology of the Italian Society of Nephrology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6650503" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : X-linked inheritance of Alport syndrome: family P revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16114783" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Alport syndrome in southern Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34400539" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Prevalence Estimates of Predicted Pathogenic COL4A3-COL4A5 Variants in a Population Sequencing Database and Their Implications for Alport Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2517321" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Renal prognosis in Alport's and related syndromes: influence of the mode of inheritance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19129241" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Autosomal dominant Alport syndrome: molecular analysis of the COL4A4 gene and clinical outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7211891" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Alport's syndrome. A report of 58 cases and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18094725" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Inherited diseases of the glomerular basement membrane.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14717907" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Ear and kidney syndromes: molecular versus clinical approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32820599" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Vestibular and audiological findings in the Alport syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3981875" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The clinical spectrum of hereditary nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17071739" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Characterization of the peripheral retinopathy in X-linked and autosomal recessive Alport syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11920343" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Renal transplant in patients with Alport's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7379367" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Perimacular changes in Alport's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20450313" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Giant macular hole in Alport syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8587250" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Smooth muscle tumors associated with X-linked Alport syndrome: carrier detection in females.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21380622" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Alport syndrome and leiomyomatosis: the first deletion extending beyond COL4A6 intron 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11024509" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Ruptured intracranial aneurysm in an adolescent with Alport's syndrome--a new expression of type IV collagenopathy: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17697765" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Ruptured thoracoabdominal aortic aneurysm in a renal transplant patient with Alport's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20494893" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Aortic abnormalities in males with Alport syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8433568" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Molecular genetics of Alport syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2349482" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Identification of mutations in the COL4A5 collagen gene in Alport syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8132760" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Deletions in the COL4A5 collagen gene in X-linked Alport syndrome. Characterization of the pathological transcripts in nonrenal cells and correlation with disease expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10752524" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20378821" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Genotype-phenotype correlation in X-linked Alport syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14514738" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a "European Community Alport Syndrome Concerted Action" study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4028523" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Renal prognosis in women with hereditary nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17400558" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Alport syndrome and the X chromosome: implications of a diagnosis of Alport syndrome in females.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33048202" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Long-term outcome among females with Alport syndrome from a single pediatric center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33391746" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Prevalence of clinical, pathological and molecular features of glomerular basement membrane nephropathy caused by COL4A3 or COL4A4 mutations: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37163122" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The Phenotypic Spectrum of COL4A3 Heterozygotes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10049589" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Identification and characterization of a highly conserved protein absent in the Alport syndrome (A), mental retardation (M), midface hypoplasia (M), and elliptocytosis (E) contiguous gene deletion syndrome (AMME).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10432421" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Making the diagnosis of Alport's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9848783" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : High mutation detection rate in the COL4A5 collagen gene in suspected Alport syndrome using PCR and direct DNA sequencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10561141" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Detection of mutations in the COL4A5 gene in over 90% of male patients with X-linked Alport's syndrome by RT-PCR and direct sequencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16941480" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A two-tier approach to mutation detection in the COL4A5 gene for Alport syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Identification of alpha 3, alpha 4, and alpha 5 chains of type IV collagen as the primary target for the alport post-transplant anti-GBM alloantibodies (abstract)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1468159" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Kidney transplantation in Alport's syndrome: long-term outcome and allograft anti-GBM nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14717941" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Retransplantation in Alport post-transplant anti-GBM disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12436246" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Unusual deep intronic mutations in the COL4A5 gene cause X linked Alport syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17660027" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Genetic testing for X-linked Alport syndrome by direct sequencing of COL4A5 cDNA from hair root RNA samples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24033287" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Unbiased next generation sequencing analysis confirms the existence of autosomal dominant Alport syndrome in a relevant fraction of cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24854265" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Improving mutation screening in familial hematuric nephropathies through next generation sequencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29987460" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Expert consensus guidelines for the genetic diagnosis of Alport syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15149316" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A large tandem duplication within the COL4A5 gene is responsible for the high prevalence of Alport syndrome in French Polynesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10201025" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Alport syndrome: is diagnosis only skin-deep?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34930753" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Guidelines for Genetic Testing and Management of Alport Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7398144" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Hereditary nephropathy (Alport syndrome): correlation of clinical data with glomerular basement membrane alterations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8914010" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Alport syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14531812" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Epidermal basement membrane alpha 5(IV) expression in females with Alport syndrome and severity of renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8178947" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Type IV collagen alpha 5 chain. Normal distribution and abnormalities in X-linked Alport syndrome revealed by monoclonal antibody.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10200983" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Identification of COL4A5 defects in Alport's syndrome by immunohistochemistry of skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7579094" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Mutation in alpha 5(IV) collagen chain gene in nonfamilial hematuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22461141" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33159213" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults-an update for 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32299679" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19846849" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Strict blood-pressure control and progression of renal failure in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20016211" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Angiotensin receptor blocker reduces proteinuria independently of blood pressure in children already treated with Angiotensin-converting enzyme inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23748277" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Alport syndrome: the effects of spironolactone on proteinuria and urinary TGF-β1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17039334" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The effect of aldosterone blockade in patients with Alport syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14745635" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Enalapril in children with Alport syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21285125" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Efficacy and safety of losartan in children with Alport syndrome--results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22166847" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26248473" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Long-term treatment by ACE inhibitors and angiotensin receptor blockers in children with Alport syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27402170" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Prospective study on the potential of RAAS blockade to halt renal disease in Alport syndrome patients with heterozygous mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32712167" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Genotype-phenotype correlations influence the response to angiotensin-targeting drugs in Japanese patients with male X-linked Alport syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33772369" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Genotype-phenotype correlations and nephroprotective effects of RAAS inhibition in patients with autosomal recessive Alport syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10027943" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Long-term effects of cyclosporine A in Alport's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17024394" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Cyclosporin therapy in patients with Alport syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20238228" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Cyclosporine A treatment in patients with Alport syndrome: a single-center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12595505" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Cyclosporine a slows the progressive renal disease of alport syndrome (X-linked hereditary nephritis): results from a canine model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34359984" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Hereditary Podocytopathies, Alport Syndrome, and FSGS: A Case Series to Better Plan a Large-Scale Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36411058" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Effects of Bardoxolone Methyl in Alport Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1635348" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : The pathogenesis of Alport syndrome involves type IV collagen molecules containing the alpha 3(IV) chain: evidence from anti-GBM nephritis after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3514017" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Linear glomerular IgG fixation in renal allografts: incidence and significance in Alport's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2212860" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Posttransplant anti-glomerular basement membrane nephritis in related males with Alport syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8196274" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : COL4A5 gene deletion and production of post-transplant anti-alpha 3(IV) collagen alloantibodies in Alport syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7993995" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : COL4A5 deletions in three patients with Alport syndrome and posttransplant antiglomerular basement membrane nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3050571" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Alport's syndrome: risk of glomerulonephritis induced by anti-glomerular-basement-membrane antibody after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7527877" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Characterization of anti-GBM antibodies involved in Goodpasture's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8738805" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Identification of 17 mutations in ten exons in the COL4A5 collagen gene, but no mutations found in four exons in COL4A6: a study of 250 patients with hematuria and suspected of having Alport syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9507224" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Targets of alloantibodies in Alport anti-glomerular basement membrane disease after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7783419" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : A COL4A3 gene mutation and post-transplant anti-alpha 3(IV) collagen alloantibodies in Alport syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7780062" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Autosomal recessive Alport syndrome: mutation in the COL4A3 gene in a woman with Alport syndrome and posttransplant antiglomerular basement membrane nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16236801" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Distinct epitopes for anti-glomerular basement membrane alport alloantibodies and goodpasture autoantibodies within the noncollagenous domain of alpha3(IV) collagen: a janus-faced antigen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16911486" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Renal transplantation in patients with Alport syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19028755" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Living donor kidney transplantation from relatives with mild urinary abnormalities in Alport syndrome: long-term risk, benefit and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19171688" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Women with Alport syndrome: risks and rewards of kidney donation.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
